First Subject Dosed with FTX-101. This study marks the beginning of a journey toward a potential treatment for chronic optic neuropathy, a condition that severely impacts vision due to the demyelination of the optic nerve.
Find Therapeutics today announced the closing of a $8.1 million (CAD$11 million) convertible note financing led by Investissement Québec with participation from current investors
We are pleased to announce clearance of our IND by the U.S. Food and Drug Administration (FDA) for a Phase 1 study of FTX-101 …
Our Chief Executive Officer, Philippe Douville, Ph.D., will present at the Bloom Burton & Co. Healthcare Investor …
Philippe Douville, Find’s Chief Executive Officer and Robert Glanzman, Find’s Chief Medical Officer will participate …
Board-certified neurologist and Fellow of the American Academy of Neurology with over 20 years experience…
Dr. Antel is an internationally acclaimed clinical neurologist and thought leader who coordinates the multiple sclerosis research and treatment …
The clinical advisory board will guide the company in the development of its autoimmune programs in demyelinating diseases …
Find Therapeutics Inc., a biopharmaceutical company, today announced the appointment of Paul F. Truex …
SATT1 Conectus and Find Therapeutics Sign Licensing Agreement to Develop a Promising New Therapy for Multiple Sclerosis
We are pleased to announce accomplished biotechnology executive and entrepreneur, Dr. Philippe Douville as its new Chief Executive …
Find Therapeutics, a new drug development company dedicated to breakthrough therapies against rare diseases launches in Montreal…